Activated Human Umbilical Cord Blood Platelet-Rich Plasma Enhances the Beneficial Effects of Human Umbilical Cord Mesenchymal Stem Cells in Chemotherapy-Induced POF Rats

Wang, Jiawei; Zhao, Yunxiao; Zheng, Fengque; Ma, Nana; Qin, Rongyan; Qin, Weili; Liu, Bo; Qin, Aiping

doi:10.1155/2021/8293699

Cited by 11 publications

(13 citation statements)

References 56 publications

(60 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Wang J et al found that human cord blood plateletrich plasma could promote proliferation and reduce apoptosis of hUMSCs. Co-transplantation hUMSCs with human cord blood platelet-rich plasma could increase the number of MSCs homing to the ovary of POF rats, which more effectively restored the estrous cycle and repaired damaged follicles of POF rats (176). In addition, Xu H et al indicated that co-transplantation of BMSCs and endothelial progenitor cells could promote angiogenesis in the site of osteonecrosis of the femoral head (183).…”

Section: Pretreatment and Co-transplantationmentioning

confidence: 99%

Bone marrow mesenchymal stem cells in premature ovarian failure: Mechanisms and prospects

Huang

Zhu²,

Liu³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Premature ovarian failure (POF) is a common female reproductive disorder and characterized by menopause, increased gonadotropin levels and estrogen deficiency before the age of 40 years old. The etiologies and pathogenesis of POF are not fully clear. At present, hormone replacement therapy (HRT) is the main treatment options for POF. It helps to ameliorate perimenopausal symptoms and related health risks, but can’t restore ovarian function and fertility fundamentally. With the development of regenerative medicine, bone marrow mesenchymal stem cells (BMSCs) have shown great potential for the recovery of ovarian function and fertility based on the advantages of abundant sources, high capacity for self-renewal and differentiation, low immunogenicity and less ethical considerations. This systematic review aims to summarize the possible therapeutic mechanisms of BMSCs for POF. A detailed search strategy of preclinical studies and clinical trials on BMSCs and POF was performed on PubMed, MEDLINE, Web of Science and Embase database. A total of 21 studies were included in this review. Although the standardization of BMSCs need more explorations, there is no doubt that BMSCs transplantation may represent a prospective therapy for POF. It is hope to provide a theoretical basis for further research and treatment for POF.

show abstract

Section: Pretreatment and Co-transplantationmentioning

confidence: 99%

Bone marrow mesenchymal stem cells in premature ovarian failure: Mechanisms and prospects

Huang

Zhu²,

Liu³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Compared to that in the NR group, vimentin expression significantly increased in the HucMSCs group (231.2 ± 13.92 vs 197.0 ± 14.41, P = 0.014) and MT-HucMSCs group (243.3 ± 19.6 vs 197.0 ± 14.41, P < 0.001). PCNA is an objective index used to evaluate cell proliferative state [37]. We observed that PCNA was mainly distributed in the nuclei of endometrial epithelial cells and luminal epithelial cells (Figure 8A and B).…”

Section: Resultsmentioning

confidence: 94%

“…After obtaining informed consent, we collected donated human umbilical cord tissue from six healthy women aged 25-30 years who gave birth. According to the previous scheme [37], we prepared HucMSCs using the method of the tissue block adherence, and the specific scheme was as follows: we washed the collected umbilical cord three times with phosphate-buffered saline (PBS) (Gibco, USA, 10010) containing 10% antibiotics to remove blood and mucus, cut the umbilical cord into small pieces of tissue (1 × 1 mm 3 ) using ophthalmic scissors, and attached it to the bottom of a Petri dish. To cover the Petri dishes with tissue, we slowly added Dulbecco's modified Eagle medium (DMEM) (Gibco, USA, 31053-028) containing 10% fetal bovine serum (FBS) (Gibco, USA, 10270).…”

Section: Isolation and Culture Of Hucmscsmentioning

confidence: 99%

Melatonin-pretreated human umbilical cord mesenchymal stem cells improved endometrium regeneration and fertility recovery through macrophage immunomodulation in rats with intrauterine adhesions

Qin,

Wang,

et al. 2023

Biology of Reproduction

Self Cite

View full text Add to dashboard Cite

Intrauterine adhesions (IUA) are a common gynecological problem. Stem cell therapy has been widely used in the treatment of IUA. However, due to the complex and harsh microenvironment of the uterine cavity, the effectiveness of such therapy is greatly inhibited. This study aimed to investigate whether melatonin pretreatment enhances the efficacy of human umbilical cord mesenchymal stem cells (HucMSCs) in IUA treatment in rats. First, we explored the effect of melatonin on the biological activity of HucMSCs in vitro through a macrophage co-culture system, CCK-8, EdU, flow cytometry, immunofluorescence staining, and qRT-PCR. Subsequently, we established the IUA rat model and tracked the distribution of HucMSCs in this model. In addition, we observed the number of M1 and M2 macrophages through immunofluorescence staining and detected the levels of inflammatory cytokines. Four weeks after cell transplantation, HE, Masson, and immunohistochemical staining were performed. In vitro experiments showed that melatonin pretreatment of HucMSCs promoted proliferation, reduced apoptosis, up-regulated the stemness gene, and regulated macrophage polarization. In vivo, melatonin pretreatment caused more HucMSCs to remain in the uterine cavity. Melatonin-pretreated HucMSCs recruited more macrophages, regulated macrophage polarization, and reduced inflammation. Melatonin-pretreated HucMSCs relieved fibrosis, increased endometrium thickness, and upregulated CD34, vimentin, PCNA, and α-SMA expression. Fertility tests showed that melatonin-pretreated HucMSCs increased the number of embryos. In summary, pretreatment with melatonin was beneficial for HucMSC treatment because it enhanced the cell’s ability to recruit macrophages and regulate macrophage polarization, which led to the regeneration of the endometrium and improved pregnancy outcomes.

show abstract

“…In terms of ovarian regeneration, Buigues et al [61] compared the effect of hUC plasma (rich in many GFs) to that of mobilizing G-CSF treatment and demonstrated that both therapies increased the populations of growing follicles, proliferation, and angiogenesis, in addition to restoring fertility of mice with gonadotoxic damage. Furthermore, Wang et al [210] observed the ample benefits of hUC-PRP treatment in a murine model of POI, including preserved ovarian morphology, regulated hormonal levels and estrous cyclicity, increased angiogenesis, and reduced apoptosis, with respect to the untreated groups. The up and down arrows, respectively, indicate an increase and decrease.…”

Section: Plasma and Platelet-rich Plasmamentioning

confidence: 99%

Human Umbilical Cord-Based Therapeutics: Stem Cells and Blood Derivatives for Female Reproductive Medicine

Rodríguez-Eguren

Gómez-Álvarez²,

Francés-Herrero

et al. 2022

IJMS

View full text Add to dashboard Cite

There are several conditions that lead to female infertility, where traditional or conventional treatments have limited efficacy. In these challenging scenarios, stem cell (SC) therapies have been investigated as alternative treatment strategies. Human umbilical cord (hUC) mesenchymal stem cells (hUC-MSC), along with their secreted paracrine factors, extracts, and biomolecules, have emerged as promising therapeutic alternatives in regenerative medicine, due to their remarkable potential to promote anti-inflammatory and regenerative processes more efficiently than other autologous treatments. Similarly, hUC blood derivatives, such as platelet-rich plasma (PRP), or isolated plasma elements, such as growth factors, have also demonstrated potential. This literature review aims to summarize the recent therapeutic advances based on hUC-MSCs, hUC blood, and/or other plasma derivatives (e.g., extracellular vesicles, hUC-PRP, and growth factors) in the context of female reproductive medicine. We present an in-depth analysis of the principal molecules mediating tissue regeneration, compiling the application of these therapies in preclinical and clinical studies, within the context of the human reproductive tract. Despite the recent advances in bioengineering strategies that sustain delivery and amplify the scope of the therapeutic benefits, further clinical trials are required prior to the wide implementation of these alternative therapies in reproductive medicine.

show abstract

Activated Human Umbilical Cord Blood Platelet-Rich Plasma Enhances the Beneficial Effects of Human Umbilical Cord Mesenchymal Stem Cells in Chemotherapy-Induced POF Rats

Cited by 11 publications

References 56 publications

Bone marrow mesenchymal stem cells in premature ovarian failure: Mechanisms and prospects

Bone marrow mesenchymal stem cells in premature ovarian failure: Mechanisms and prospects

Melatonin-pretreated human umbilical cord mesenchymal stem cells improved endometrium regeneration and fertility recovery through macrophage immunomodulation in rats with intrauterine adhesions

Human Umbilical Cord-Based Therapeutics: Stem Cells and Blood Derivatives for Female Reproductive Medicine

Contact Info

Product

Resources

About